PDCD1 and melanoma: A combination therapy of Ipilimumab and Nivolumab, which targets PD-1, was subsequently approved for melanoma following data from the Checkmate 067 trial, which demonstrated an OS benefit for the combination therapy versus Ipilimumab monotherapy (15).